Neurofibrillary degeneration of the Alzheimer-type: an alternate pathway to neuronal apoptosis?

Neuronal death is a process which may be either physiological or pathological. Apoptosis and necrosis are two of these processes which are particularly studied. However, in neurodegenerative disorders, some neurons escape to these types of death and "agonize" in a process referred to as neurofibrillary degeneration. Neurofibrillary degeneration is characterized by the intraneuronal aggregation of abnormally phosphorylated microtubule-associated Tau proteins. A number of studies have reported a reactivation of the cell cycle in the neurofibrillary degeneration process. This reactivation of the cell cycle is reminiscent of the initiation of apoptosis in post-mitotic cells where G1/S markers including cyclin D1 and cdk4/6, are commonly found. However, in neurons exhibiting neurofibrillary degeneration, both G1/S and G2/M markers are found suggesting that they do not follow the classical apoptosis and an aberrant cell cycle occurs. This aberrant response leading to neurofibrillary degeneration may be triggered by the sequential combination of three partners: the complex Cdk5/p25 induces both apoptosis and the "abnormal mitotic Tau phosphorylation". These mitotic epitopes may allow for the nuclear depletion of Pin1. This latter may be responsible for escaping classical apoptosis in a subset of neurons. Since neurofibrillary degeneration is likely to be a third way to die, molecular mechanisms leading to changes in Tau phosphorylation including activation of kinases such as cdk5 or other regulators such as Pin1 could be important drug targets as they are possibly involved in early stages of neurodegeneration.

[1]  A. Delacourte,et al.  Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease , 2002, Neurology.

[2]  M. Goedert,et al.  Phosphorylation of microtubule‐associated protein tau by stress‐activated protein kinases in intact cells , 2002, FEBS letters.

[3]  S. Estus,et al.  Analysis of cell cycle-related gene expression in postmitotic neurons: Selective induction of cyclin D1 during programmed cell death , 1994, Neuron.

[4]  Xiongwei Zhu,et al.  Neurons in Alzheimer disease emerge from senescence , 2001, Mechanisms of Ageing and Development.

[5]  T. Arendt,et al.  Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus , 2002, Acta Neuropathologica.

[6]  J. Noel,et al.  Critical Role of WW Domain Phosphorylation in Regulating Phosphoserine Binding Activity and Pin1 Function* , 2002, The Journal of Biological Chemistry.

[7]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[8]  A. Delacourte,et al.  Abnormal Tau phosphorylation of the Alzheimer‐type also occurs during mitosis , 2002, Journal of neurochemistry.

[9]  Tianhua Niu,et al.  Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c‐Jun towards cyclin D1 , 2001, The EMBO journal.

[10]  L. Buée,et al.  1H NMR Study on the Binding of Pin1 Trp-Trp Domain with Phosphothreonine Peptides* , 2001, The Journal of Biological Chemistry.

[11]  A. Delacourte,et al.  Induction of a specific tau Alzheimer epitope in SY‐5Y neuroblastoma cells , 1996, Neuroreport.

[12]  G. Halliday,et al.  Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies , 2001, Acta Neuropathologica.

[13]  P. Greengard,et al.  Neuron‐Specific Phosphorylation of Alzheimer's β‐Amyloid Precursor Protein by Cyclin‐Dependent Kinase 5 , 2000, Journal of neurochemistry.

[14]  David S. Park,et al.  Role of Cell Cycle Regulatory Proteins in Cerebellar Granule Neuron Apoptosis , 1999, The Journal of Neuroscience.

[15]  T. Arendt,et al.  Neuronal expression of cycline dependent kinase inhibitors of the INK4 family in Alzheimer's disease , 1998, Journal of Neural Transmission.

[16]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[17]  D. Dickson,et al.  Mitotic phosphoepitopes precede paired helical filaments in Alzheimer’s disease , 1998, Neurobiology of Aging.

[18]  E. Mandelkow,et al.  Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. , 1998, European journal of biochemistry.

[19]  E. Mandelkow,et al.  Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress , 2002, The Journal of cell biology.

[20]  P. Davies,et al.  The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein , 1999, Nature.

[21]  G. Jicha,et al.  Aberrant Expression of Mitotic Cdc2/Cyclin B1 Kinase in Degenerating Neurons of Alzheimer’s Disease Brain , 1997, The Journal of Neuroscience.

[22]  J. H. Wang,et al.  Cyclin-dependent kinase 5 (Cdk5) and neuron-specific Cdk5 activators. , 1996, Progress in cell cycle research.

[23]  P. Davies,et al.  Mitotic mechanisms in Alzheimer's disease? , 1996, The Journal of cell biology.

[24]  K. Herrup,et al.  The induction of multiple cell cycle events precedes target-related neuronal death. , 1995, Development.

[25]  A. Delacourte,et al.  Mitotic-like Tau Phosphorylation by p25-Cdk5 Kinase Complex* , 2003, Journal of Biological Chemistry.

[26]  A. Delacourte,et al.  Pathological Tau Phenotypes: The Weight of Mutations, Polymorphisms, and Differential Neuronal Vulnerabilities , 2000, Annals of the New York Academy of Sciences.

[27]  P. Davies,et al.  Deregulation of cdk5, Hyperphosphorylation, and Cytoskeletal Pathology in the Niemann–Pick Type C Murine Model , 2002, The Journal of Neuroscience.

[28]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[29]  N. Cairns,et al.  Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms , 1992, Neuron.

[30]  A. Delacourte,et al.  Modelling Alzheimer‐specific abnormal Tau phosphorylation independently of GSK3β and PKA kinase activities , 2002, FEBS letters.

[31]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[32]  M. Mattson,et al.  Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease , 1998, Nature Medicine.

[33]  Y. Liou,et al.  Proline-directed phosphorylation and isomerization in mitotic regulation and in Alzheimer's Disease. , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[34]  Qiang Yu,et al.  IGF‐1 induces Pin1 expression in promoting cell cycle S‐phase entry , 2002, Journal of cellular biochemistry.

[35]  R. Neve,et al.  Alzheimer’s disease: a dysfunction of the amyloid precursor protein 1 1 Published on the World Wide Web on 11 September 2000. , 2000, Brain Research.

[36]  U Dirnagl,et al.  Mild Cerebral Ischemia Induces Loss of Cyclin-Dependent Kinase Inhibitors and Activation of Cell Cycle Machinery before Delayed Neuronal Cell Death , 2001, The Journal of Neuroscience.

[37]  Masafumi Nakamura,et al.  Pin1 regulates turnover and subcellular localization of β-catenin by inhibiting its interaction with APC , 2001, Nature Cell Biology.

[38]  A. Ryo,et al.  Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer , 2003, Journal of Cell Science.

[39]  I. Vincent,et al.  Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases , 2000, Neurobiology of Aging.

[40]  M. Ball,et al.  A topographical pathway by which histopathological lesions disseminate through the brain of patients with Alzheimer's disease , 1991 .

[41]  Patrick R. Hof,et al.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.

[42]  L. Tsai,et al.  Neurotoxicity induces cleavage of p35 to p25 by calpain , 2000, Nature.

[43]  A. Delacourte,et al.  Pin1: a therapeutic target in Alzheimer neurodegeneration. , 2002, Journal of molecular neuroscience : MN.

[44]  Brian J Cummings,et al.  Immunohistochemical evidence for apoptosis in Alzheimer's disease. , 1994, Neuroreport.

[45]  S. Tsang,et al.  Research communication copper-1,10-phenanthroline induces internucleosomal DNA fragmentation in HepG2 cells, resulting from direct oxidation by the hydroxyl radical. , 1996, The Biochemical journal.

[46]  L. Tsai,et al.  Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration , 1999, Nature.

[47]  Z. Nagy Cell cycle regulatory failure in neurones: causes and consequences , 2000, Neurobiology of Aging.

[48]  S. Lovestone,et al.  Neurofibrillary tangles and tau phosphorylation. , 2001, Biochemical Society symposium.

[49]  K. Jellinger,et al.  Alzheimer Disease: DMA Fragmentation Indicates Increased Neuronal Vulnerability, but not Apoptosis , 1998, Journal of neuropathology and experimental neurology.

[50]  G. Jicha,et al.  A Conformation‐ and Phosphorylation‐Dependent Antibody Recognizing the Paired Helical Filaments of Alzheimer's Disease , 1997, Journal of neurochemistry.